In August 2003, Salus Therapeutics was acquired by Genta, Inc. Salus Therapeutics, Inc., focuses on the research and development of nucleic acid-based therapeutics, including antisense and gene therapy drugs. The Company's technology, licensed from and developed at the University of Utah, allows the rapid identification of "optimal" antisense targets on any gene of interest. Salus will use this technology to identify targets on a variety of disease related genes. Antisense therapeutics of greatest potency and specificity will be developed against identified targets, either internally, or through licensing agreements with interested third parties. In addition to MS, the Company is developing products for the treatment of cystic fibrosis, inflammatory disease, diabetes and cancer.
